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Abstract Damage to the central nervous system triggers rapid
activation and speci¢c migration of glial cells towards the lesion
site. There, glial cells contribute heavily to secondary neuronal
changes that take place after lesion. In an attempt to identify
the molecular cues of glial activation following brain trauma we
performed di¡erential display reverse transcription-polymerase
chain reaction screenings from lesioned and control hippocam-
pus. Here we report on the identi¢cation of the macrophage/
microglia activation factor (MAF), a new membrane protein
with seven putative transmembrane domains. Expression analy-
sis revealed that MAF is predominantly expressed in microglial
cells in the brain, and is upregulated following brain lesion.
Overexpression of MAF in non-glial cells shows an intracellular
codistribution with the lysosomal marker endosome/lysosome-
associated membrane protein-1 (lamp-1). Furthermore, MAF-
transfected cells show that MAF is primarily associated with
late endosomes/lysosomes, and that this association can be dis-
rupted by activation of protein kinase C-dependent pathways. In
conclusion, these results imply that MAF is involved in the
dynamics of lysosomal membranes associated with microglial
activation following brain lesion.
+ 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Brain damage, such as stroke and trauma, induces substan-
tial remodeling of neuronal structures and connectivity [1^3].
Such remodeling is driven by endogenous neuronal programs
reinitiating embryonic growth feasibility as well as by glial
activation responses [4,5]. A well-characterized system for an-
alyzing these phenomena is the entorhino-hippocampal lesion
model [6]. Axons from the entorhinal cortex terminate in a
laminar-speci¢c fashion in the hippocampus. Furthermore,
this particular axonal projection is severely altered in neuro-
degenerative conditions such as Alzheimer’s disease, leading
to microglial activation, axonal degeneration, and disconnec-
tion of the limbic structure [7^9]. Microglia are cells of the
monocyte/macrophage lineage naturally populating the brain
parenchyma [10]. There, they exist in two major functional
states: non-activated (rami¢ed, or resting) and activated (ame-
boid). Lesioning the entorhinal cortex induces a rapid activa-
tion and migration of microglial cells to the site of the injury,
a feature also found in neurodegenerative diseases [11,12].
This activation induces an ameboid-like phenotype in micro-
glial cells which is associated with enhanced phagocytotic ac-
tivity, the expression of various immunomodulatory factors,
and the secretion of in£ammatory and cytotoxic molecules
leading to secondary neuronal damage [2,13,14].
In an attempt to identify which molecules are associated
with the activation of microglial cells and secondary damage
to neurons, we performed a di¡erential display screening with
cDNAs obtained from lesioned hippocampi [15]. Here we re-
port on the identi¢cation of a new macrophage/microglia ac-
tivation factor (MAF). MAF is expressed by microglial cells
following activation. Expression analysis revealed that MAF
is predominantly expressed in the brain. Thus, we identi¢ed a
membrane protein with seven putative transmembrane do-
mains speci¢cally expressed by microglial cells. We also
show that MAF is associated with endosome/lysosome-asso-
ciated membrane protein-1 (lamp-1) positive late endosomes/
lysosomes and its expression is upregulated following lesion.
Furthermore, MAF-associated vesicular structures are se-
creted in a protein kinase C (PKC)-dependent manner. Our
data suggest that activated microglial cells have a neurotoxic
role which may contribute to secondary neuronal degenera-
tion following brain lesion.
2. Materials and methods
2.1. Animal manipulation and tissue isolation
Adult male Sprague rats (200^250 g weight) obtained from our
central animal facility (Tierexperimentelle Einrichtung Charite¤, Dr.
S. Nagel) were kept under standard laboratory conditions in accor-
dance with the German and European Guidelines for the use of lab-
oratory animals (in congruence with 86/609/EEC). All surgical proce-
dures were performed in agreement with the German law on the use
of laboratory animals. For stereotactic surgery, rats were anesthetized
with a mixture of 25 mg/ml ketamine (CuraMed Pharma GmbH,
Karlsruhe, Germany), 1.2 mg/ml xylazine (Bayer, Leverkusen, Ger-
many) and 0.35 mg/ml acepromazine (Sano¢ GmbH, Du«sseldorf, Ger-
many) in 0.9% sterile NaCl (2.5 ml/kg body weight intraperitoneally
(i.p.)) and received a unilateral entorhinal cortex lesion (ECL) through
the use of a stereotaxic headholder (Stoelting, Germany) [15]. In brief,
a standard electrocoagulator was used to make bilateral incisions
(with four single pulses (2.5 WA) for 3 s each) in the frontal and
sagittal planes between the entorhinal cortex and hippocampus. The
following coordinates measured from lambda were used: frontal in-
cision: AP +1.2, L 3.1 to 6.1, and V down to the inferior cranium;
sagittal incision: AP +1.2 to +4.2, L 6.1, and V down to the inferior
cranium [16]. Rats were allowed to survive for 1 and 10 days (n=4
animals per stage for in situ hybridization; n=6 animals at 1 day after
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lesion (dal) for di¡erential display reverse transcription-polymerase
chain reaction (DDRT-PCR) and Northern blot analysis). The rats
were decapitated under deep ether anesthesia (Chinosol, Germany).
2.2. Di¡erential mRNA display and molecular cloning
For DDRT-PCR, the hippocampi of six lesioned (1 dal stage) and
six untreated control animals were rapidly removed and washed in
0.1 M phosphate bu¡er and subsequently frozen in liquid nitrogen.
Total RNA was extracted from the hippocampi using the guanidinium
thiocyanate-phenol-chloroform extraction method [17]. DNA-free
RNA was obtained by treatment with RNase-free DNase I (Boehr-
inger, Germany) for 30 min at 37‡C. After phenol-chloroform extrac-
tion and ethanol precipitation, the probes were stored at 380‡C. The
¢rst strand reactions contained 50 ng oligo(dt11-NN), 400 units of
superscript II RT3 transcriptase and 100 nM dithiothreitol (DTT)
in 20 Wl 1Utranscription bu¡er (all from Gibco, Germany) and
were incubated with 2 Wg RNA and 200 WM deoxyribonucleoside
triphosphate (dNTP) (Pharmacia Biotech, Germany) for 1 h at
42‡C. Following ¢rst strand synthesis, two units of RNase H3 (Gibco,
Germany) were added and the reactions were incubated at 37‡C for
30 min. The cDNA was puri¢ed using the PCR puri¢cation kit (Qia-
gen, Germany). PCR was performed using 2 Wl of the RT reaction per
25 Wl. All reactions were performed in quadruples. Anchor and arbi-
trary primers (Roth, Germany) were used in di¡erent combinations.
Reactions were performed in 25 mM MgCl2, 2.5 Wl 10Ureaction buf-
fer, 2.5 units Amplitaq Gold (all from Perkin Elmer, USA), 200 mM
dNTP (Pharmacia Biotech, Germany), 20 pmol per anchor primer
and 10 pmol per arbitrary primer. The cycler program was: 95‡C,
10 min; 40‡C, 90 s; 72‡C, 45 s followed by 39U(94‡C, 30 s; 40‡C,
90 s; 72‡C, 45 s); 5 min at 72‡C, and then soaked at 4‡C. For electro-
phoretic separation, the entire PCR reaction was precipitated with
ethanol. For the analysis of the PCR products, the CleanGel DNA
analysis kit and the DNA silver staining kit (both from Pharmacia
Biotech, Germany) were used according to the manufacturer’s instruc-
tions. Those bands di¡ering in expression between lesioned and con-
trol animals were excised and reampli¢ed in 25 Wl reaction using the
same conditions as before. The resulting fragments were cloned into
the pCR02.1-TOPO Vector (Invitrogen, The Netherlands) and se-
quenced. MAF full-length clones were ampli¢ed by RT-PCR from
postnatal and adult rat and mouse hippocampus cDNA and human
hemapoetic cell lines. Database searches used BLAST on the website
of the National Center for Biotechnology Information (NCBI). Multi-
ple sequence alignments were made with Clustal W using the DNAsis
Max v1.1 software (Hitachi, Olivet Cedex, France). Transmembrane
structures were predicted with ProDom, PREDICT PROTEIN,
TMPRED, and SwissProt databases. The rat MAF sequence is
deposited at the NCBI homepage (GenBank accession number
AF540876). The MAF open reading frame was further tagged with
enhanced green £uorescent protein (eGFP) at the N-terminus and at
the C-terminus and cloned into a pcDNA 3.1 based vector (Invitro-
gen, Germany). Both, N-terminal tagged MAF as well as C-terminal
tagged MAF showed essentially the same subcellular distribution.
2.3. Northern blot analysis
The isolation of RNA from brains was performed as described
under Section 2.2. Messenger RNA from cell lines was isolated with
MidiMACS mRNA isolation columns (Miltenyi Biotec, Bergisch
Gladbach, Germany). A total of 20 Wg of RNA from six adult control
and six 1 dal animals was loaded on a 1% agarose gel containing
formaldehyde, transferred to Hybond1-N membrane (Amersham
Life Science, UK) and crosslinked by ultraviolet irradiation. As a
probe for MAF, the 1240 bp di¡erential display fragment was used.
A cDNA L-actin fragment ampli¢ed by RT-PCR served as a control
for mRNA integrity and amounts of mRNA loaded. Primers for the
ampli¢cation of the control gene L-actin were: L-actin 5P (5P-CAC
CAC AGC TGA GAG GGA AAT CGT GCG TGA-3P) spanning
bases 2395^2424, and L-actin 3P (5P-ATT TGC GGT GCA GCA
TGG AGG GGC CGG ACT-3P) complementary to bases 3095^
3124, with an ampli¢cation length of 520 bp for rat L-actin cDNA
(GenBank accession number J00691). PCR was performed in 25 Wl
¢nal volume containing 1 mM dNTP (Pharmacia Biotech, Germany),
2.5 units Taq polymerase (Perkin Elmer, USA), 2.5 Wl 10Ubu¡er
including 2.5 M MgCl2 (Perkin Elmer, USA), 10 WM of each primer,
and 1 Wl cDNA using a Thermo-Cycler PTC-100 (MJ Research, Inc.,
USA). The cycle program was: 95‡C, 2 min; 35U(94‡C, 30 s; 70‡C,
30 s; 72‡C, 2 min); and 72‡C, 10 min. Both probes were labeled with
the Prime-a-Gene Labeling System (Promega, USA) and [32P]dCTP
(DuPont NEN, USA). Hybridization was performed in 10 ml hybrid-
ization solution (250 mM sodium phosphate, pH 7.2, 7% sodium
dodecyl sulfate (SDS), 0.5 mM ethylenediamine tetraacetic acid
(EDTA), 1% bovine serum albumin (BSA)) at 60‡C for 12 h. The
membrane was washed in 2Ustandard sodium citrate (SSC) at
room temperature, 0.2USSC at room temperature, and 0.2USSC at
40‡C for 30 min each. Membranes were exposed to Kodak X-OMAT
AR X-ray ¢lms at 380‡C for 20 h, using an intensifying screen.
2.4. In situ hybridization
For in situ hybridization experiments, four brains per lesion stage
were dissected and frozen in the gaseous phase of liquid nitrogen.
Horizontal cryostat sections (15 Wm) were ¢xed in 4% paraformalde-
hyde (w/v), washed in 0.1 M phosphate bu¡er saline (PBS, pH 7.4)
and dehydrated. For in situ hybridization the following oligonucleo-
tides were used: antisense oligonucleotides 5P-CAT GAG CCA GAT
AAA CCA ACG CAT ATG AGA TGC CAG-3P and 5P-ACA ATG
GCC CGA ACA ATG AGG AAT GCG TGT GTG TAG C-3P
complementary to rat and mouse MAF mRNA (GenBank accession
number AF540876) and their sense oligonucleotides. Both oligonu-
cleotides gave essentially the same hybridization results. The speci¢c-
ity of oligonucleotides was con¢rmed by a BLAST GenBank search
(www.ncbi.nlm.nih.gov) and showed no signi¢cant crossmatches with
known sequences and expressed sequence tags (ESTs). The oligonu-
cleotides were end-labeled using terminal deoxynucleotide transferase
(Boehringer, Germany) and [K-35S]deoxyadenosine triphosphate
(dATP) (DuPont NEN, USA), and used for in situ hybridization.
Hybridization was performed for 16 h at 42‡C in a humidi¢ed cham-
ber after which the slides were washed as follows: 2U30 min in
1USSC at 56‡C and 1U10 min in 0.5USSC at room temperature.
Finally, the sections were rinsed in H2O at room temperature and
dehydrated. Slides were exposed to Kodak X-OMAT AR X-ray
¢lm for autoradiography for 20 days. Sections hybridized with sense
oligonucleotides and sections hybridized with antisense oligonucleoti-
des in the presence of antisense oligonucleotides in 40-fold surplus
served as controls. These controls showed only background hybridi-
zation signals. After exposure, slides were counterstained with cresyl
violet [18].
2.5. Quantitative in situ hybridization analysis
Four animals were analyzed by in situ hybridization for each post-
lesion time point and the unlesioned control values. For each animal,
two in situ hybridization autoradiographs of adjacent brain slices were
used to quantify signal strength. The quanti¢cation was performed as
described [18]. In brief, for analysis of these images, a computerized
videodensitometry system (Metamorph Universal Imaging Inc. West-
Chester, PA, USA) was used to quantify the signal intensity on a
600U600 dpi resolution. A visually established pixel intensity thresh-
old was set to remove the unlabeled portion of the image. A rectangle
(1.5 mm2) was de¢ned and placed in 10 di¡erent positions over the
lesion site (brain parenchyma). For each position, the percentage of
pixels within the rectangle representing signal intensities higher than
the threshold was determined; signal intensities above this value were
not further discriminated. Gray scale values between 0 and 255 were
assigned to the grayness of autoradiographic images, the background
(less than 20 gray scale values) was subtracted, and the corresponding
relative optical density was determined. Data were corrected for ¢lm
background and expressed in relative optical density. A mean value of
the 10 measurements was calculated for each region and set in refer-
ence to the unlesioned controls (100%). Analysis was performed using
the Mann^Whitney U-test. The level of signi¢cance was set at
P6 0.05 (Statview II, Abacus, Berkeley, CA, USA).
2.6. Cell culture and subcellular localization
COS-7 cells (ATCC: CRL-1651) and BV-2 microglial cells (kindly
provided by Dr. V. Bocchini, University of Perugia, Italy) were
routinely maintained at 37‡C with 5% CO2 in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 Wg/ml streptomycin as described [19]. Isolation and
culture of primary neurons was performed as described [20]. Trans-
fections with the pMAF-eGFP and peGFP-N1 (BD Clontech, Heidel-
berg, Germany) constructs were performed by Amaxa Nucleofector
electroporation (Amaxa Biosystems, Ko«ln, Germany) revealing nearly
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90% green £uorescent cells. Hoechst staining was performed accord-
ing to the protocol by Brauer et al. [19]. Images were taken with a
CCD camera on a Leica DM LB microscope. Digital data were pro-
cessed with MetaVue 4.62 software. All constructs were validated by
DNA sequencing prior transfection experiments (Dr. S. Prehn, Center
for Biochemistry, Charite¤ University Medical School, Berlin, Ger-
many). Cell viability was measured with the MTT assay and nuclear
factor (NF)-UB translocation was assayed via immunoblots from nu-
clear fractions [20].
2.7. Lysosomal staining and immuno£uorescence
COS-7 cells and BV-2 microglial cells were ¢xed with 4% parafor-
maldehyde in phosphate bu¡er (150 mM NaCl, pH 7.4) for at least
30 min, quenched by 5 min incubation in 50 mM NH4Cl, and per-
meabilized with phosphate bu¡er containing 0.1% Triton X-100
(Merck, Germany) for 10 min. Lamp-1 antibody (Developmental
Studies Hybridoma Bank, Iowa City, IA, USA) was incubated for
6 h at 4‡C, washed three times for 10 min, and incubated with an
IgG immune-absorbed Alexa 5681 antibody (Molecular Probes) for
Fig. 1. MAF nucleotide and amino acid sequence. A: Rat MAF nucleotide and amino acid sequence (GenBank accession number AF540876).
The putative transmembrane domains (TM1^TM7) are boxed in blue. Start and stop codons are marked in red boxes. The putative glycosyla-
tion site is boxed in yellow. B: Hydrophobicity pro¢le of MAF predicted by Kyte^Doolittle algorithms and a window size of ¢ve residues.
Numbers in the bottom refer to amino acid residues from the amino-terminus.
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1 h at room temperature. LysoTracker1 staining was performed ac-
cording to the manufacturer’s instructions (Molecular Probes, Eu-
gene, OR, USA). Specimens were processed for immuno£uorescence
microscopy, mounted on Immu-Mount (Thermo-Shandon, Pitts-
burgh, PA, USA) and viewed on a Leica DM LB microscope. All
images were taken with a standardized exposure protocol: texp = 5.25 s
for GFP channel; texp = 3.20 s for tetrarhodamine isothiocyanate
(TRITC) channel; texp = 0.12 s for HOECHST. Quanti¢cation of
number and size of late endosomes/lysosomes and vesicles was per-
formed with the MetaMorph analysis system (Universal Imaging, PA,
USA). Precise measurements of distances of endosomes/lysosomes
from the nucleus were performed in three independent experiments
for each cell line with n=20 per experiment. For statistical analysis
Statview II was used (Abacus, USA).
3. Results
3.1. Identi¢cation of MAF
By DDRT-PCR screening of randomly ampli¢ed cDNAs
from lesioned and non-lesioned control rat hippocampi, we
identi¢ed a 1240 bp fragment with high homology to EST
clones coding for hemolysin-like genes in vertebrates and pro-
karyotes. Full-length cloning from brain cDNAs revealed a
single 2563 bp product which was directly T/A cloned. After
insert size analysis, this clone was subjected to sequencing and
the orthologue was revealed to be an uncharacterized human
macrophage-speci¢c cDNA [21] (GenBank accession number
AF540876) (Fig. 1A). Computer structural analysis (HMM-
TOP, PREDICT PROTEIN, TMHMM, TMPRED) consis-
tently predicted that MAF cDNA encodes for a membrane
protein with seven transmembrane domains. In silico Gen-
Bank searches revealed further that these hydrophobic do-
mains are highly conserved in the animal kingdom, from bac-
teria to humans. GenBank searches for orthologous proteins
show that the MAF is highly conserved in mammals (human/
mouse/rat s 95%), and partial EST sequences indicate orthol-
ogous proteins in bacteria, Caenorhabditis elegans, Drosophila
and in other invertebrate genomes as well. This gene encodes
Fig. 2. MAF is upregulated following brain lesion. A: MAF mRNA upregulation following lesion. Di¡erential display mRNA analysis was
carried out with 2 Wg total RNA of dea¡erentiated hippocampi 1 dal and non-lesioned control hippocampi (con). One PCR product represent-
ing the MAF fragment shows a stronger band in the lanes of lesioned hippocampi versus lanes with the control hippocampi (red arrows).
B: Northern blot analysis of MAF transcripts in non-lesioned controls and lesioned hippocampi (1 dal). A strong upregulation of MAF
mRNA following lesion is shown (black arrow). C: MAF mRNA expression in the adult non-lesioned hippocampus (con) and in the lesioned
hippocampus (dal). Red arrows indicate the increased expression in brain parenchyma following lesion. Right image shows a consecutive brain
section (1 dal) stained with cresyl violet (Nissl). Arrows indicate areas of increased MAF mRNA expression. Scale bars represent 1.8 mm.
D: Quantitative analysis of MAF mRNA expression in the hippocampus following lesion. For each lesion stage, three animals received an
ECL and were killed at 1, 3, 5, 10, and 28 dal. Data are expressed as percentage values compared to non-lesioned controls. Error bars indicate
W S.D. Statistical signi¢cance is marked with an asterisk (P6 0.05; Mann^Whitney U-test).
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Fig. 3. Tissue distribution of MAF transcripts. A: Multi-tissue Northern blot analysis of MAF mRNA shows a single 2.6 kb band in the
brain. B: RT-PCR from NIH 3T3, HT22, PC12, BV-2, COS-7, HEK293, SH-SY5Y, primary (1st) neurons, and pMAF vector (10 ng) serving
as a positive control. Arrowheads indicate the reference size from the PstI-digested V phage. L-actin RT-PCR indicates equal cDNA quality.
Fig. 4. MAF is associated with endosomes/lysosomes in COS-7 and microglial cells. Overexpression of eGFP-tagged MAF (green) in COS-7
cells (A) and BV-2 microglial cells (B) and subsequent immunohistochemical analysis reveal colocalization with a marker of late endosomes
and endosomes/lysosomes, lamp-1 (red). Di¡erential interference contrast (DIC) images show healthy COS-7 cells. MAF is localized in cytoplas-
matic vesicles, which are colocalized with the lysosomal marker lamp-1 (arrows). Note that the organization of MAF-associated vesicles appears
more dynamic as their size exhibits greater heterogeneity (0.2^3 Wm). They are dispersed from the nucleus and border the plasma membrane.
Scale bars in A: 25 Wm; in B: 9 Wm. C: Cell viability of COS-7 cells 24 h after transfection. Note that MAF overexpression did not signi¢-
cantly a¡ect cell viability. Error bars indicate W S.D.
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an as yet uncharacterized membrane protein with seven puta-
tive hydrophobic domains (Fig. 1B).
RT-PCR and Northern blot analysis revealed one distinct
band of 2.6 kb size in lesioned hippocampi, whereas only
weak hybridization signals appeared in the lanes of non-le-
sioned control hippocampus (Fig. 2A, B).
In situ hybridization analysis highlighted lesion-induced
regulation of MAF speci¢cally in the denervated area of the
hippocampus (Fig. 2C, D). This lesion-induced MAF upreg-
ulation was restricted to the a¡ected area, whereas non-af-
fected brain areas did not show any altered expression (Fig.
2C, D). We further investigated the tissue distribution of
MAF mRNA and found predominantly brain tissue as a
source of MAF expression (Fig. 3A). Since brain tissue con-
tains primarily neuronal and glial cells, we further elucidated
the source of MAF expression. RT-PCR analysis revealed
MAF expression mainly in microglial cells (BV-2), whereas
neuronal cells were devoid of MAF expression (primary neu-
rons, HT22, PC12, SH-SY5Y) (Fig. 3B). Furthermore, at least
one cell line which does not originate from the monocyte/
macrophage hemapoetic line (NIH 3T3 cells) also expresses
MAF (Fig. 3B).
Fig. 5. MAF secretion is mediated in a PKC-dependent manner. A: Distribution of eGFP in COS-7 cells. Note that eGFP is homogeneously
distributed throughout the cytoplasm and does not codistribute to lamp-1 positive vesicles. B: Distribution of eGFP-tagged MAF in COS-7
cells. In transfected cells MAF was typically detected in small (0.2^1.0 Wm) cytoplasmic, vesicular-like structures located in the cytoplasmatic
periphery (green). All MAF positive vesicles show colocalization with lamp-1 (red). C and D: Treatment of COS-7 cells with PMA, an en-
hancer of exocytosis, for 10 and 30 min. 10 min after PMA treatment, MAF/lamp-1 positive vesicles show a wide and increased distribution
throughout the cytoplasmatic periphery. 30 min after PMA application almost all MAF vesicles vanished. E: COS-7 cells treated with BFA, a
blocker for the tra⁄c of secretory proteins from the ER to the Golgi complex. Note the accumulation of lamp-1 positive as well as MAF-asso-
ciated vesicles in the cytoplasm. Scale bar represents 15 Wm.
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3.2. MAF is associated with mature endosomes/lysosomes
To gain some insight into the subcellular distribution and
possible function of MAF, we constructed vectors bearing the
wild-type MAF and MAF tagged with an eGFP. Cells were
transfected by a modi¢ed electroporation method and subse-
quently immunostained with anti-lamp-1 antibody. In COS-7
and microglial cells, MAF appeared concentrated in vesicular
structures densely scattered in the cell body mainly juxtanu-
clearly and underneath the plasma membrane (Fig. 4A, B).
Occasionally, MAF was localized in some larger juxtanuclear
vesicular structures and in di¡use, ¢ne, punctate cytoplasmic
structures in addition to vesicles, whereas MAF was not
present in the nucleus (Fig. 4B). Both eGFP fusion to MAF
at the N-terminus as well as eGFP tag at the C-terminus gave
essentially the same subcellular distribution (data not shown).
The organization of the MAF-associated vesicular structures
exhibited great heterogeneity, as their size ranged from 0.2 Wm
up to 3 Wm (Table 1).
Next we analyzed the nature of the MAF positive vesicular
structures. Given their peripheral distribution and round
shape we hypothesized that these structures are of endocytic
origin: endosomes, recycled endosomes or late endosomes/
lysosomes [22]. To test this we performed double staining
using markers for mature or secondary endosomes/lysosomes
[23]. Indeed, using the marker lamp-1, we were able to dem-
onstrate that the MAF-associated vesicles are lamp-1 positive
(Fig. 4A, B). In transfected cells, cytoplasmic MAF labeling
and anti-lamp-1 staining were coincident. Nearly all MAF
positive vesicles were positive for lamp-1 but some lamp pos-
itive endosomes/lysosomes were not labeled for MAF. To
con¢rm the lysosomal localization and to exclude possible
artefacts and mistargeting due to overexpression, we used:
(i) transfection with a vector solely bearing the reporter
gene eGFP,
(ii) microglial cells, which endogenously express MAF.
Transfection with the wild-type MAF-bearing vector or
with eGFP-tagged MAF did not a¡ect cell viability or
stress-induced NF-UB activation (Fig. 4C). Transfection ex-
periments in BV-2 microglial cells con¢rmed that MAF is
speci¢cally localized in late endosomal/lysosomal compart-
ments (Fig. 4B, Table 1). Controls expressing solely eGFP
showed a distinct subcellular organization to MAF, with a
homogeneous distribution throughout the cytoplasm unre-
lated to lamp-1 positive vesicles (Fig. 5A).
3.3. MAF is excreted in a PKC-dependent manner
In order to analyze the functional association of MAF with
endosomes/lysosomes, and to demonstrate that MAF overex-
pression does not arti¢cially a¡ect intracellular processing and
cell function, we decided to take a pharmacological approach
to lysosomal secretion. COS-7 and microglial cells were there-
fore treated with phorbol-12 myristate-13 acetate (PMA), a
strong PKC activator, and endosomes/lysosomes were moni-
tored (Fig. 5B^D). 10 min after PMA treatment, MAF/lamp-1
positive vesicles showed a wide distribution throughout the
cytoplasmatic periphery (Fig. 5C). 30 min after PMA appli-
cation, most of the lamp-1 positive vesicles disappeared (Fig.
5D). To the same extent, MAF positive vesicles vanished after
PMA incubation, whereas eGFP expressing controls exhibited
no £uorescence change (data not shown). Treatment of COS-7
cells with brefeldin A (BFA), a blocker for the tra⁄c of se-
cretory proteins from the ER to the Golgi complex, revealed
an inverse situation. BFA treatment retained MAF and lamp-
1 positive vesicles reversibly. In addition, the MAF/lamp-1
colocalized vesicles increased during the course of BFA appli-
cation (Fig. 5D). Furthermore, MAF-associated vesicles accu-
mulated around the nucleus and in the cytosol and codis-
tributed with the lamp-1 positive compartment (Fig. 5E).
Transfection of BV-2 microglial cells revealed the same dy-
namic distribution of MAF positive vesicles after PMA treat-
ment as found in COS-7 cells (data not shown).
4. Discussion
In this study, we describe the identi¢cation, expression, reg-
ulation and distribution of a new late endosome/lysosome-
associated molecule, MAF, which is speci¢cally expressed in
microglial cells. MAF is upregulated following ECL during
periods characterized by glial activation and neuronal degen-
eration. Microglial activation has detrimental e¡ects on neu-
ronal survival and connectivity following brain lesion [9].
Once activated, microglial cells transform into an ameboid-
like phenotype [13] and migrate towards the lesion site [12,24],
where they secrete in£ammatory and cytotoxic molecules,
such as tumor necrosis factor (TNF)-K and interleukin (IL)-
1L [14,25], phagocytose neuronal debris, and sublethally dam-
aged neurons [9,26,27]. The combination of these processes
leads to secondary brain damage, accounting for most of
the volume of damaged brain area and loss of brain function
[2]. The expression and activation of lysosomal enzymes com-
mence prior to the onset of neuronal apoptosis and cell death,
indicating that microglia are actively involved in this process
[9,28,29]. Blockage of microglial activation following brain
damage has bene¢cial e¡ects on neuronal outcomes, such as
survival, dendritic and axonal morphology, and regenerative
axon growth [14,30]. Speci¢cally, interference with the lyso-
somal pathway in microglial cells can prevent secondary neu-
ronal damage [2,14]. By means of DDRT-PCR from lesioned
brain tissue, we identi¢ed the MAF, a new membrane protein
with seven transmembrane domains. Expression analysis re-
vealed that MAF shows a distribution in late endosomes/ly-
sosomes. Consistent with this is a putative N-glycosylation site
localized at the cytoplasmatic/luminal site of MAF. Further-
more, MAF shows a dynamic intracellular regulation. MAF is
primarily associated with late endosomes/lysosomes, and this
association can be disrupted by activation of PKC-dependent
pathways.
Recently, a new membrane progesterone receptor family
(mPR) has been identi¢ed in spotted seatrout oocytes [31].
It has been suggested that these molecules encode plasma
membrane proteins with seven putative transmembrane do-
Table 1
MAF-associated vesicles in COS-7 cells and BV-2 microglial cells
Size of lamp-1/MAF immunopositive vesicular structures
COS-7 cells BV-2 microglial cells
Vesicular size in Wm n Vesicular size in Wm n
0.2^1.0 36W 8 0.2^1.0 29W 7
s 1.0^2.0 9W 5 s 1.0^2.0 5W 3
s 2.0 4W 1.9 s 2.0 2W 1
All lamp-1 positive MAF containing vesicular-like structures were
submitted for counting by two independent observers. Results are
meansWS.D. per cell (n=20 per experiment out of three sets of ex-
periments).
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mains. Multiple sequence alignments revealed that MAF
shows 71% homology to mPR10 and almost 99% identity to
mPR11. So far, the exact cellular distribution of mPR10 and
mPR11 has not been proven. Our results indicate that MAF is
associated with late endosomes/lysosomes. However, the exact
function of MAF remains to be established. It is conceivable
that MAF acts as a receptor or sensor on late endosomes/
lysosomes, but we cannot yet exclude the possibility that
MAF also acts as an anchoring sca¡old or modulator and
regulator of membrane transport towards lysosomal compart-
ments and secretion. On the other hand, it is also possible that
MAF is targeted to the plasma membrane and acts as a sensor
for chemotaxis, since lysosomes are able to fuse with the sur-
face plasma membrane [32].
In conclusion, these results imply that MAF is involved in
the dynamics of late endosomal/lysosomal membranes of mi-
croglial cells. Moreover, MAF is expressed by activated mi-
croglial cells, which may contribute to the secondary neuronal
degeneration following brain lesion. Thus, future studies using
gene silencing approaches (siRNA techniques or genetic dis-
ruption strategies) will provide further insights into the role of
MAF during microglial^neuronal interactions.
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